# EDGAR Filing Document

**Accession Number:** 0001472091
**File Stem:** 0001140361-25-021742
**Filing Date:** 2025-6
**Character Count:** 2663
**Document Hash:** 5d201135b73cb508df33d2b3d6f916e0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-021742.hdr.sgml**: 20250710

**ACCESSION NUMBER**: 0001140361-25-021742

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250606

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PDS Biotechnology Corp
- **CENTRAL INDEX KEY:** 0001472091
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 264231384
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 303A COLLEGE ROAD EAST
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
- **BUSINESS PHONE:** 800-208-3343

**MAIL ADDRESS:**
- **STREET 1:** 303A COLLEGE ROAD EAST
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Edge Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20090911

#### PDS BIOTECHNOLOGY CORPORATION

#### 303A College Road East

#### Princeton, NJ 08540

June 6, 2025

#### VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Alan Campbell

---

| | |
|:---|:---|
| **RE:** | **PDS Biotechnology Corporation** |
|  | **Registration Statement on Form S-3** |
|  | **Filed May 27, 2025** |
|  | **File 333-287588** |
|  | **Acceleration Request** |

---

Dear Mr. Campbell:

With respect to the above-referenced Registration Statement on Form S-3 (the "Registration Statement"), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of PDS Biotechnology Corporation (the "Company"), that the Securities and Exchange Commission accelerate the effective date of the Registration Statement to Tuesday, June 10, 2025, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter, unless we or our outside counsel, DLA Piper LLP (US), request by telephone that such Registration Statement be declared effective at some other time.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Please call Fahd Riaz of DLA Piper LLP (US), counsel to the Company, at (215) 656-3316, with any comments or questions regarding the Registration Statement.

---

| |
|:---|
| Very truly yours, |
| PDS Biotechnology Corporation |
| /s/ Frank Bedu-Addo |
| Frank Bedu-Addo |
| Chief Executive Officer |

---

cc: Patrick O'Malley, Esq., *DLA Piper LLP (US)* <br> Dylan Caplan, Esq., *DLA Piper LLP (US)*

------